SCHEMBL4215643

SCHEMBL4215643

O=C(O)c1ccc(-c2ccccc2)cc1Nc1cccc2cccnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.52
▸ PLEC Q15149 1/20 0.52
▸ ACLY P53396 2/20 0.51
▸ KDR P35968 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ ALDH1A1 P00352 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ POLB P06746 2/20 0.45
▸ RECQL P46063 1/20 0.45
▸ CASP3 P42574 1/20 0.45
▸ SENP8 Q96LD8 1/20 0.45
▸ SENP7 Q9BQF6 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ P4HB P07237 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10505456 0.85 ALDH1A1 (0.60) MAPTPLECKDRSMN1; SMN2MEN1
SCHEMBL4217318 0.82 MAPT (0.49) MAPTPLECKDRSMN1; SMN2MEN1
SCHEMBL4211086 0.82 GLO1 (0.51) MAPTPLECKDRSMN1; SMN2MEN1
SCHEMBL22000089 0.80 ACLY (0.72) ACLYMEN1KMT2ATDP1
SCHEMBL4226821 0.78 KDM4C (0.50) ACLYMEN1KMT2ACYP2C9
SCHEMBL4218109 0.76 ACMSD (0.60) ACLYKDM4ERECQL
SCHEMBL4217337 0.76 FABP3 (0.73) ACLYKDM4ERECQL
SCHEMBL4216661 0.74 FTO (0.58) MAPTACLYMEN1KMT2ALMNA
SCHEMBL4223433 0.74 FABP4 (0.58) ACLYMEN1KMT2ALMNAKDM4E
SCHEMBL4214728 0.74 ACLY (0.54) ACLYKDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 — — US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 — — EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 — — US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 MAPT 4791/4885PLEC 4389/4885ACLY 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback